CEDAR KNOLLS, NJ–(May 11, 2015) – MYOS Corporation (“MYOS” or the “Company”) (NASDAQ: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today the initiation of a dose response clinical study of Fortetropin® in modestly resistance trained subjects. The study, led by, Jacob Wilson, Ph.D, CSCS*D, Professor of Health Sciences and Human Performance at the University of Tampa, will examine the effects of Fortetropin® supplementation on plasma myostatin levels at various dosing levels. The clinical study will help better define the dose response curve, the minimal effective dose and effects of Fortetropin® on serum myostatin.

In this double blind placebo controlled clinical study, 80 subjects will be randomized to four groups who will be supplemented with three different doses of Fortetropin® and a matching placebo. The study will examine the effect of various doses of Fortetropin® on plasma levels of myostatin and compare them to placebo.

Robert Ashton, M.D., Chief Medical Officer of MYOS, commented, “This study continues to build upon our current knowledge of Fortetropin®, a natural myostatin modulator that has been proven to enhance muscle growth. It is our hypothesis that lowering dosing levels will allow Fortetropin® to be formulated into new products and modes of delivery.”

Dr. Wilson commented, “Our team is very excited to continue studying Fortetropin® in our human performance laboratory.”

About Dr. Jacob Wilson

Dr. Wilson is renowned for his research centered around the training and nutrition variables that enhance skeletal muscle mass, strength and power at the University of Tampa. As the Director of the state-of-the-art Skeletal Muscle and Sports Nutrition Laboratory, Dr. Wilson has established one of the most advanced centers researching cellular, molecular and body changes in muscle size, strength and power in response to resistance training and nutrition interventions. He has published more than 150 peer-reviewed papers, books, and abstracts. Among other honors, Dr. Wilson is the 2013 Recipient of the National Strength and Conditioning Association Young Investigator of the Year Award.

About MYOS Corporation
MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin®, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as “The Muscle Company,”™ visit www.myoscorp.com

About Rē Muscle Health™
The Rē Muscle Health™ series is the Company’s first branded line of muscle health products. This unique line of all-natural, non-GMO products contain Fortetropin®, an egg-based, all natural myostatin inhibitor clinically proven to build healthy muscle. The Rē Muscle Health™ series can be ordered by visiting www.remusclehealth.com. MYOS believes that Fortetropin®, as well as future products it envisions, will redefine existing standards for muscle health. The Rē Muscle Health™ product line is owned and sold directly by the Company. www.remusclehealth.com

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin® and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, customer demand for our Rē Muscle Health™ and other products, the continued growth of repeat purchases, market acceptance of our existing and future products, the ability to create new products through research and development, growth in our revenue, the successful entry into new markets including the age management market, the ability to successfully launch our own Rē Muscle Health™ products, the ability to collect our accounts receivable from our distributors, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin® and Rē Muscle Health™, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to comply with NASDAQ’s continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

MYOS Corporation Investor and Media Contact:

Lindsey Penrose
Vice President Business Development
(973) 509-0444
Email Contact